Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path
TCTMD,
At $6,500 per year, without outcomes data, inclirisan faces hurdles. Doctors still expect it to be “transformative.” Healthcare…
At $6,500 per year, without outcomes data, inclirisan faces hurdles. Doctors still expect it to be “transformative.” Healthcare…
Leslie Cho CHICAGO —Intermittent statin dosing is a treatment option that may have tremendous potential for addressing patients…
Leslie Cho CHICAGO —Intermittent statin dosing is a treatment option that may have tremendous potential for addressing patients…
Most patients who report statin intolerance, including muscle aches and other side effects from the cholesterol-lowering drugs…